13 out of 29 study centres in Austria, Germany and Poland have begun recruiting participants for the trial of the PoCCardio point-of-care solution. The plan is to engage over 1800 heart patients.

The objective of the clinical trial is to assess the effect of an intensified risk-factor management guided by biomarkers and the use of the point-of-care (PoC) instrument.

By using biomarker-based diagnostics, the study aims to identify individuals at extremely high risk of recurrent cardiovascular events. It will evaluate the impact of intensifying treatment for residual risk on cardiovascular outcomes in these extremely high-risk individuals, compared to standard therapy as outlined in current guidelines. Additionally, the trial will explore the use of the PoC instrument for companion diagnostics, adjusting treatment intensity based on biomarker values.

The trial will take place across 29 clinical centres in Austria, Germany and Poland, having received regulatory approval in May 2025. Recruitment is already underway at thirteen sites in Austria and Germany, with Poland to follow soon. The study aims to enrol over 1800 patients who have experienced a recent myocardial infarction.